Fenamic acid

• UNSPSC Description:

  Fenamic acid (N-Phenylanthranilic acid, NPAA) is an orally active chloride channel blocker. Fenamic acid is the basic constituent of non-steroidal anti-inflammatory agents (NSAIA), and derives into mefenamic, tofenacin, flufenac acid and melofenac acid. Fenamic acid also acts as antibacterial and analgesic agent[1]-[6].

• Target Antigen:

  Chloride Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/fenamic-acid.html

• Purity:

  98.19

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(O)C1=CC=CC=C1NC2=CC=CC=C2

• Molecular Weight:

  213.236

• References & Citations:

  [4]Betton GR, et, al. Biomarkers of collecting duct injury in Han-Wistar and Sprague-Dawley rats treated with N-phenylanthranilic Acid. Toxicol Pathol. 2012 Jun;40(4):682-94.|[5]Endo S, et al. Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid. Biol Pharm Bull. 2010. 33(5):886-90.|[6]Seong YJ, et al. Repurposing Fenamic Acid Drugs To Combat Multidrug-Resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2020 Jun 23. 64(7):e02206-19.|[7]Almasirad A, et al. Synthesis and analgesic activity of 2-phenoxybenzoic acid and N-phenylanthranilic acid hydrazides. Biol Pharm Bull. 2006 Jun. 29(6):1180-5. |[1]Betton GR, et, al. Biomarkers of collecting duct injury in Han-Wistar and Sprague-Dawley rats treated with N-phenylanthranilic Acid. Toxicol Pathol. 2012 Jun;40(4):682-94.|[2]Mandel KG, et al. Characterization of a cyclic AMP-activated Cl-transport pathway in the apical membrane of a human colonic epithelial cell line. J Biol Chem. 1986 Jan 15. 261(2):704-12.|[3]Ueda S, et al. Chloride efflux in cyclic AMP-induced configurational change of bovine pulmonary artery endothelial cells. Circ Res. 1990 Apr. 66(4):957-67.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  91-40-7